AUTHORS
Eric O'Brien, MBA, Mithun Sarangdhar, Ph.D.2, Brett VanCauwenbergh3, Mitali Basu4, Gabriel Wahler5, LaQuita M Jones, DO6, John Perentesis, MD7
AFFILIATIONS
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
5 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
6 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
ABSTRACT
Background
Although 5-Azacitidine and Venetoclax (Aza-Ven) have transformed Acute Myeloid Leukemia (AML) therapy, clinical durability is frequently limited by primary and acquired resistance driven by compensatory RAS/MAPK pathway activation. Daraxonrasib is a first-in-class, noncovalent RAS(ON) multi-selective inhibitor that overcomes traditional single-mutation constraints by engaging cyclophilin A (CypA) to form a tri-complex (CypA–Daraxonrasib–RAS). This assembly creates a bulky steric barrier that physically occludes downstream effector binding (e.g., RAF) across multiple active/on, GTP-bound RAS variants. Leveraging this unique pan-RAS steric blockade, we performed unbiased high-throughput single agent and combination screening in 37 cell lines and patient samples to identify Daraxonrasib sensitive lines and those that would benefit from the combination of Aza-Ven+Daraxonrasib. Daraxonrasib was tested against a genetically diverse panel encompassing canonical hotspot mutations (NRAS G12D/G13D/Q61L, KRAS Q61H), upstream drivers (FLT3-ITD, KIT N822K), and fusion-driven leukemias including KMT2A::MLLT4 (MLL-AF6), whose wild-type MLLT4 RAS-associating RA1 domain directly binds active RAS.
Methods
Daraxonrasib was systematically evaluated across 37 genetically diverse cell lines (29 AML, 3 B-ALL, 5 rhabdomyosarcoma [RMS]) as a single agent and in combination with Aza-Ven. Additionally, a 113-compound screen was conducted in combination with a fixed 1:10 Aza-Ven molar ratio backbone across six AML cell lines. Pharmacologic profiling consisted of single-agent dose–response assays (0.02–10,000 nM) and Daraxonrasib-Aza-Ven 8x8 combination matrices. Drug synergy was quantified using ΔBliss where 0 denotes additivity and the more negative the values are denotes greater synergy.
Results
Daraxonrasib ranked first among 113 compounds (mean ΔBliss, -11.81), followed by the MCL-1 inhibitors MIK665 (-11.05) and AZD-5991 (-10.95). Across 29 AML models, median single-agent IC50 was 254 nM (range, 4.1 to ≥10,000), and 13/29 (44.8%) had IC50 ≤100 nM. All 29 models had negative combination scores (median, -7.16; range, - 23.98 to -1.28), and 12/29 (41.4%) had scores ≤-10. Cell lines with single-agent IC50 ≤100 nM (n=13) had a median 3.46-fold potency shift and median ΔBliss of -5.93, whereas models with IC50 ≥1,000 nM (n=13) showed a median 70.5-fold shift and median ΔBliss of -10.51, consistent with Aza-Ven creating resistance signaling through the RAS/MAPK pathway that can be targeted with RAS(ON) inhibition. Direct RAS-mutant AML models (n=11) had a median ΔBliss of -13.88, with all scores ≤-5 despite heterogeneous single-agent potency. NB-4 (KRAS A18D) showed an incomplete-killing plateau with Daraxonrasib alone but the strongest combination interaction (ΔBliss, -23.98; 637-fold potency shift), consistent with a cytostatic-like single-agent response. B-ALL comparators had IC50 ≥10,000 nM and minimal potency shifts (1.0-1.25-fold). PAX3-FOXO1 RMS models showed no measurable single-agent response or combination potentiation (IC50 ≥10,000 nM; fold shift, 1; ΔBliss ≥0), whereas NRAS Q61H RMS (RD) was single-agent sensitive (IC50, 200 nM) but not combination-potentiated, supporting treatment- and lineage-context dependence. Among three models annotated as KMT2A::MLLT4, CTS and SHI-1 had low-nanomolar single-agent IC50 values (4.1 and 12.6 nM); 2022-178-H was insensitive alone but sensitized with Aza-Ven (combination-associated IC50, 11.7 nM; 855-fold shift; ΔBliss, -18.61).
Conclusions
Daraxonrasib emerged as a top enhancer of Aza-Ven, ranking above MCL-1 inhibitors and avoiding their associated cardiotoxicities, while demonstrating broad combination synergy across AML models including robust potency shifts in single-agent-resistant phenotypes. Low nM single agent Daraxonrasib IC50’s were observed in receptor tyrosine kinases such as FLT3-ITD and KIT mutant AML lines whose signaling is upstream of RAS. This same level of potency was also observed in several BCR-ABL1 and KMT2A::MLLT4 fusion driven cell lines. These findings highlight translational strategies leveraging RAS(ON) inhibition with Daraxonrasib to treat RAS mutant and RAS/MAPK pathway activating mutations and to mitigate RAS/MAPK signaling resistance to Aza-Ven in AML. Overall, these results warrant mechanistic and functional validation of Daraxonrasib plus Aza-Ven to support future clinical development in AML.
DISCLOSURES
Eric O'Brien, MBA: No relevant conflicts of interest to declare.